885271-78-3 Usage
Uses
Used in Pharmaceutical Industry:
6-BROMO-3-CHLORO-1H-INDAZOLE is used as a key intermediate in the synthesis of novel therapeutic agents. Its unique molecular structure and functional groups allow for the development of new drugs with potential applications in various therapeutic areas, such as oncology, cardiovascular diseases, and neurological disorders. 6-BROMO-3-CHLORO-1H-INDAZOLE's versatility in chemical reactions enables the creation of a wide range of drug candidates with improved efficacy and selectivity.
Used in Agrochemical Industry:
6-BROMO-3-CHLORO-1H-INDAZOLE is used as a starting material in the development of new pesticides. Its chemical properties make it suitable for the synthesis of active ingredients with enhanced insecticidal, herbicidal, or fungicidal properties. By incorporating 6-BROMO-3-CHLORO-1H-INDAZOLE into the design of new agrochemicals, researchers can potentially develop more effective and environmentally friendly pest control solutions.
Check Digit Verification of cas no
The CAS Registry Mumber 885271-78-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,5,2,7 and 1 respectively; the second part has 2 digits, 7 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 885271-78:
(8*8)+(7*8)+(6*5)+(5*2)+(4*7)+(3*1)+(2*7)+(1*8)=213
213 % 10 = 3
So 885271-78-3 is a valid CAS Registry Number.
InChI:InChI=1/C7H4BrClN2/c8-4-1-2-5-6(3-4)10-11-7(5)9/h1-3H,(H,10,11)
885271-78-3Relevant academic research and scientific papers
HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES
-
Paragraph 000216, (2016/05/02)
Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions in need of inhibition of heparan sulfate biosynthesis.
DIFLUOROMETHYLENE COMPOUND
-
Paragraph 0519-0522, (2015/06/16)
The present invention relates to a compound having an URAT1 inhibitory activity, and to an URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition containing the compound. More specifically, the present invention relates to a compound represented by the formula (I): wherein R1 is -Q1-A1 or the like; R2 is a hydrogen atom, a halogen atom, a lower alkyl group or the like; W1, W2, W3 and W4 are each independently a nitrogen atom or a methine group optionally having substituents, or the like; X and Y are each a single bond, an oxygen atom or the like; Z is a hydroxyl group or COOR3 or the like.
